Komori
Occurring Fact4880CellSource Co.,Ltd.Pharmaceuticals

Notice Regarding the Recording of Non-Operating Expenses

A loss of ¥11 million on the operation of an investment partnership was recognized as a non-operating expense. The impact has been reflected in the results for the interim consolidated accounting period of the fiscal year ending October 2026.

Worth reading
27Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Deterioration
Direction inferred from the company’s description.
Scale
11
¥ million
Wording
Definitive
How definitive the wording is.

Recognition of non-operating expenses

Subject Entity

CellSource Co.,Ltd. (the filing company)

Target Locations / Products

Investment in an Investment Partnership

OccurrenceRecorded in the interim consolidated accounting period of the fiscal year ending October 2026 (1 November 2025 to 30 April 2026)
This disclosure06/10/2026
Cause

Loss on the operation of an investment partnership

Amount of Impact on Business Performance

¥11 million (non-operating expenses)

Accounting period in which recognized

Interim consolidated accounting period of the fiscal year ending October 2026 (1 November 2025 to 30 April 2026)

Impact on Earnings Forecast

Reflected in the Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending October 2026 [Japanese GAAP] (Consolidated), released today

Event that occurred
ItemDetails
Event nameRecognition of non-operating expenses
Date of occurrenceRecorded in the interim consolidated accounting period of the fiscal year ending October 2026 (1 November 2025 to 30 April 2026)
Subject EntityCellSource Co.,Ltd. (the filing company)
Target Locations / ProductsInvestment in an Investment Partnership
CauseLoss on the operation of an investment partnership
Amount of Impact on Business Performance¥11 million (non-operating expenses)
Accounting period in which recognizedInterim consolidated accounting period of the fiscal year ending October 2026 (1 November 2025 to 30 April 2026)
Impact on Earnings ForecastReflected in the Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending October 2026 [Japanese GAAP] (Consolidated), released today
Items this document does not state (17)
Date recognized / date notice receivedType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changeOutlookPlanned follow-up disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Based on the financial statements received concerning the investment partnership investment, a loss on the operation of the investment partnership was recognized.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Recording of Non-Operating Expenses | CellSource Co.,Ltd. (4880) timely disclosure | Komori